Washington, DC, United States of America

Thomas N Chase

This inventor holds 31 USPTO granted patents and 30 published patent applications, plus 10 CIPO patents and 9 EPO patents, primarily in Neurodegenerative Treatments. Top assignees: Chase Pharmaceuticals Corporation, Chase Therapeutics Corporation, Alto Neuroscience, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas N Chase. Retrieved from https://idiyas.com/inventor/thomas-n-chase

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 30)

% Patents Active = 87.1

CIPO Patents = 10 (Patent Applications = 15)

EPO Patents = 9 (Patent Applications = 36)

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 99(Granted Patents)

Company Filing History:

14 out of 14

Chase Pharmaceuticals Corporation

patents

7 out of 7

Chase Therapeutics Corporation

patents

3 out of 7

Alto Neuroscience, Inc.

patents

4. 3 out of 3

Avion Pharmaceuticals, LLC

patents

5. 3 out of 5

Nc Medical Research Inc.

patents

6. 1 out of 1

Chase Parmaceuticals Corporation

patent

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Combination Therapy

Dopamine Agonist

Neurodegenerative Diseases

NK-1 Antagonist

Synucleinopathies

Levodopa

Cell Therapy

Alzheimer-Type Dementia

Pharmaceutical Compositions

Muscarinic Agonist

Therapeutic System

Anticholinergic Composition

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12648934 - Combination therapy for a dopamine agonist (2026-06-09),

2. 12622895 - Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases (2026-05-12),

3. 12521374 - Combination therapy for a dopamine agonist (2026-01-13),

4. 11819485 - Levodopa fractionated dose composition and use (2023-11-21),

5. 11813248 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

6. 11813247 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

7. 11547700 - Compositions and methods for treating synucleinopathies (2023-01-10),

8. 11439613 - Levodopa fractionated dose composition and use (2022-09-13),

9. 11318122 - Pharmaceutical combination and its use for treating synucleinopathties (2022-05-03),

10. 11266633 - NK-1 antagonist compositions and methods for use in treating depression (2022-03-08),

11. 11160809 - NK1-antagonist combination and method for treating synucleinopathies (2021-11-02),

12. 11033521 - Levodopa fractionated dose composition and use (2021-06-15),

13. 10874723 - Cell therapy for the treatment of neurodegeneration (2020-12-29),

14. 10799484 - Compositions and methods for treating synucleinopathies (2020-10-13),

15. 10596139 - Oxybutynin transdermal therapeutic system muscarinic agonist combination (2020-03-24),

Title: The Inventor Thomas N Chase

Introduction: Thomas N Chase is a renowned inventor based in Washington, DC, known for his groundbreaking contributions to various fields.

Latest Patents: Thomas N Chase holds several patents in the areas of technology, healthcare, and sustainable energy, showcasing his diverse range of innovative ideas.

Career Highlights: Throughout his career, Thomas N Chase has been recognized for his inventive spirit and problem-solving skills, leading to numerous successful inventions that have made a significant impact on society.

Collaborations: Thomas N Chase has collaborated with leading research institutions, universities, and companies to bring his ideas to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: In conclusion, Thomas N Chase stands as a visionary inventor whose passion for innovation continues to drive him towards creating solutions that shape the future.

Profile summary based on public USPTO records.